Activity of selpercatinib in RET fusion-positive cancers confirmed

被引：1
|
作者：
Romero, Diana
机构：
[1] Nature Reviews Clinical Oncology,
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2022年 / 19卷 / 12期
关键词：
D O I：
10.1038/s41571-022-00694-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：747 / 747
页数：1
相关论文
共 50 条
  • [1] Activity of selpercatinib in RET fusion-positive cancers confirmed
    Diana Romero
    [J]. Nature Reviews Clinical Oncology, 2022, 19 : 747 - 747
  • [2] Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    Hendriks, Lizza E. L.
    Zhou, Caicun
    Solomon, Benjamin
    Perol, Maurice
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (04): : 381 - 382
  • [3] Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Chen, M. F.
    Rosen, E.
    Falcon, C.
    Repetto, M.
    Yang, S. R.
    Chang, J.
    Kris, M. G.
    Rekhtman, N.
    Donoghue, M.
    Drilon, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [4] Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
    Gautschi, O.
    Subbiah, V
    Konda, B.
    Bauer, T.
    McCoach, C.
    Falchook, G.
    Takeda, M.
    Patel, J.
    Weiss, J.
    Peled, N.
    Bazhenova, L.
    Soldatenkova, V
    French, P.
    Drove, N.
    Drilon, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 12 - 12
  • [5] Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC
    Tina Nie
    Yahiya Y. Syed
    [J]. Targeted Oncology, 2023, 18 : 169 - 176
  • [6] Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC
    Nie, Tina
    Syed, Yahiya Y.
    [J]. TARGETED ONCOLOGY, 2023, 18 (01) : 169 - 176
  • [7] Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers.
    Subbiah, Vivek
    Konda, Bhavana
    Bauer, Todd
    McCoach, Caroline
    Falchook, Gerald
    Takeda, Masayuki
    Patel, Jyoti
    Weiss, Jared
    Peled, Nir
    Bazhenova, Lyudmila
    Soldatenkova, Victoria
    French, Pearl
    Drove, Nora
    Gautschi, Oliver
    Drilon, Alexander
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [8] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC
    Zhou, Caicun
    Solomon, Benjamin
    Loong, Herbert H.
    Park, Keunchil
    Perol, Maurice
    Arriola, Edurne
    Novello, Silvia
    Han, Baohui
    Zhou, Jianying
    Ardizzoni, Andrea
    Mak, M. Perez
    Santini, Fernando C.
    Elamin, Yasir Y.
    Drilon, Alexander
    Wolf, Juergen
    Payakachat, Nalin
    Uh, Minji K.
    Rajakumar, Deborah
    Han, Hongmei
    Puri, Tarun
    Soldatenkova, Victoria
    Lin, A. Bence
    Lin, Boris K.
    Goto, Koichi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (20): : 1839 - 1850
  • [9] Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma
    Weiler, Daniela
    Lago, Maria del Sol Perez
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (11) : 3467 - 3468
  • [10] Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?
    Lau, Sally C. M.
    Ou, Sai-Hong Ignatius
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 561 - 563
12345